Impact of Pretreatment Total Cholesterol Level Is Associated With Metastasis of Prostate Cancer

• Published in: American journal of men's health Vol. 14; no. 2; p. 1557988320918788
• Main Authors: Hirano, Hisashi, Ide, Hisamitsu, Lu, Yan, Inoue, Yasuyuki, Okada, Hiroshi, Horie, Shigeo
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.03.2020; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: Cholesterol; Health risk assessment; Metastasis; Prostate cancer; Prostatic Disorders; metastasis; prostate cancer; hypercholesterolemia
• ISSN: 1557-9883; 1557-9891; 1557-9891
• DOI: 10.1177/1557988320918788

Metabolic syndrome is reported to play a role in the genesis and development not only of angina, arteriosclerosis, diabetes, and osteoporosis but also of prostate cancer. Hypercholesterolemia is a strong risk factor in prostate cancer development. The current study was conducted to analyze whether pretreatment serum levels of cholesterol correlate with prostate cancer metastasis. Three hundred fifty-one subjects who received a histopathological diagnosis of prostate cancer were evaluated by clinical factors such as age, body mass index (BMI), disease stage, Gleason score, prostate-specific antigen (PSA), total cholesterol, Luteinizing hormone (LH), testosterone, and free testosterone. A multivariate analysis was performed on these factors, and a statistically significant difference was identified in total cholesterol level (p =.01) and PSA (p < .001). The total cholesterol level was higher in cases of metastatic prostate cancer compared to nonmetastatic prostate cancer in this study and therefore may be a predictive factor for poor prognosis.